PROJECT STAGE
Lead optimisation
Hit to lead
Screening
Assay Development
Therapeutic area
  • Cardiovascular disease; osteolytic diseases /oncology

Project Aim

First-in-class anti-netrin-1 humanised antibody for the treatment of atherosclerosis

Advantage

An anti-netrin-1 therapeutic offers the potential to reverse atherosclerosis with an additive benefit to cholesterol reduction interventions

Target Class

Dependence Receptor Ligand

Modality

Antibody

Current Status

Lead optimisation. Antibody humanisation and in-vivo POC underway

Intellectual Property

Initial filings with the opportunity to create a protective IPR portfolio

Offering

Licence or shared risk collaboration

Key Contact

  • In submitting your personal data via this form, you consent to being contacted via the details provided so that your enquiry can be responded to. A backup of your data will be held but only authorised individuals will be able to access your data. If you would like your data to be removed, please email support@thewebkitchen.co.uk.
    Please see our Privacy policy in relation to the personal data you submit to us through this page.
All Licensing Opportunities